<DOC>
	<DOC>NCT02949128</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy of ALXN1210 to control disease activity in adolescent and adult patients with aHUS who have not previously used a complement inhibitor.</brief_summary>
	<brief_title>Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>1. Male or female ≥ 12 years of age and weighing ≥ 40 kg at the time of consent. 2. Evidence of thrombotic microangiopathy (TMA), including low platelet count, hemolysis (breaking of red blood cells inside of blood vessels), and decreased kidney function 3. Documented meningococcal vaccination not more than 3 years prior to dosing, under 18 also requiring vaccination against Streptococcus pneumoniae and Haemophilus influenzae 4. Female patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210 1. ADAMTS13 deficiency (Activity &lt; 5%) 2. Shiga toxinrelated hemolytic uremic syndrome (STECHUS) 3. Positive direct Coombs test 4. Pregnancy or breastfeeding 5. Identified drug exposure related hemolytic uremic syndrome (HUS) 6. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within last 6 months prior to start of Screening 7. HUS related to vitamin B12 deficiency 8. Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or antiphospholipid antibody positivity or syndrome 9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for ESKD)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>